Oriola

Oriola Corporation Stock Exchange Release 4 March 2026 at 10:00 a.m. EET

Oriola's Annual Report 2025 published

Oriola has today published its Annual Report for the year 2025. The Annual Report consists of the following sections: Business review, Corporate governance statement, Remuneration report, Report of the Board of Directors and Financial statements

The Report of the Board of Directors includes the Sustainability statement prepared in accordance with the European Sustainability Reporting Standards (ESRS) and Chapter 7 of the Finnish Accounting Act. The audit firm KPMG Oy Ab has performed a limited assurance engagement on the Sustainability statement.

Oriola publishes the Report of the Board of Directors and the Financial statements in accordance with European Single Electronic Format (ESEF) reporting requirements with the format of the report being Extensible Hypertext Markup Language (XHTML). In line with the ESEF requirements, the primary statements and notes to the consolidated financial statements have been labelled with iXBRL markups. The audit firm KPMG Oy Ab has provided an independent auditor's reasonable assurance report on Oriola Corporation's ESEF Financial Statements. The assurance has been completed in accordance with the international standard on assurance engagements ISAE 3000.

The Annual Report 2025, Corporate governance statement and Remuneration report as well as the ESEF Financial statements are attached as PDF documents to this release. The reports are also available on the company website at www.oriola.com/annual-report.

Oriola Corporation

Contacts:
investor.relations@oriola.com

Distribution:
Nasdaq Helsinki Ltd
Key media
www.oriola.com

Oriola Corporation Stock Exchange Release 25 February 2026 at 12.00 p.m. EET

Notice to Oriola Corporation's Annual General Meeting 2026

Notice is given to the shareholders of Oriola Corporation ("Oriola" or the "Company") to the Annual General Meeting to be held on Wednesday 25 March 2026 starting at 3:00 p.m. (EET) at Hanasaari at the address Hanasaarenranta 5, FI-02100 Espoo, Finland, the Celsius Auditorium, entrance 1st floor. The reception of persons who have registered for the meeting and distribution of the voting tickets at the meeting venue will commence at 2:00 p.m. (EET). There will be coffee service at the meeting.

Shareholders can exercise their voting rights also by voting in advance. In addition, it is possible to follow the Annual General Meeting online via webcast. For further instructions, please refer to Section C "Instructions for the Participants of the Annual General Meeting" of this notice.

A.    Matters on the Agenda of the Annual General Meeting
Information and proposals concerning the formal organisational matters in agenda items 1 to 5 are included in a separate organisational document published on the Company's website at www.oriola.com, which document also constitutes a part of this notice. The document will be supplemented at the meeting with such information that is not available before the Annual General Meeting.

At the Annual General Meeting, the following matters will be considered:

1. Opening of the Annual General Meeting
2. Calling the Annual General Meeting to order
3. Election of persons to scrutinise the minutes and to supervise the counting of votes
4. Recording the legality of the meeting
5. Recording the attendance at the meeting and adoption of the list of votes
6. Presentation of the financial statements, the consolidated financial statements, the report of the Board of Directors, the auditor's report and the sustainability reporting assurance report for the year 2025

Review by the President and CEO.

7. Adoption of the financial statements and the consolidated financial statements
8. Resolution on the use of the profit shown on the balance sheet and the payment of dividend
The Board of Directors proposes to the Annual General Meeting that a dividend of EUR 0.03 per share be paid on the basis of the balance sheet to be adopted in respect of the financial year which ended 31 December 2025. According to the proposal, the dividend would be paid to shareholders registered in the Company's shareholders' register held by Euroclear Finland Oy on the dividend record date of 27 March 2026. The Board of Directors proposes that the dividend be paid on 15 April 2026.

The Board of Directors further proposes that the Annual General Meeting authorises the Board of Directors, at its discretion, to resolve on the distribution of a possible second dividend instalment up to a maximum of EUR 0.04 per share. It is the intention of the Board of Directors that the possible dividend payment pursuant to this authorisation would be carried out in November 2026. The Company would separately publish possible resolutions of the Board of Directors on the dividend payment and confirm the record and payment dates in connection with such resolutions. The possible second instalment to be paid based on the authorisation would be paid to a shareholder who on the payment record date in question is recorded in the Company's shareholders' register maintained by Euroclear Finland Oy. The Board of Directors proposes that the authorisation includes the right for the Board of Directors to decide on all other terms and conditions related to the dividend payment. The Board of Directors may also decide not to use this authorisation. The authorisation is proposed to remain in effect until the next Annual General Meeting of the Company.

9. Resolution on the discharge of the members of the Board of Directors and the President and CEO from liability
10. Presentation of the Remuneration Report for governing bodies 
The Company's Remuneration Report for governing bodies will be published by way of a stock exchange release, and it is available on the Company's website at www.oriola.com on 4 March 2026 at the latest.

The Board of Directors proposes to the Annual General Meeting that it approves, through an advisory resolution, the Company's Remuneration Report for governing bodies.

11. Resolution on the remuneration of the members of the Board of Directors
Oriola has on 15 January 2026 announced the proposals of Oriola's Shareholders' Nomination Board to the Annual General Meeting. The Nomination Board proposes that the remunerations would be paid to the members of the Board of Directors as follows: 

The fee for the term of office of the Chairman of the Board of Directors would be EUR 71,400, the fee for the term of office of the Vice Chairman of the Board of Directors would be EUR 40,800, the fee for the term of office of the Chairman of a Board Committee, provided that the person is not the Chairman or Vice Chairman of the Board of Directors, would be EUR 40,800 and the fee for the term of office of the other members of the Board of Directors would be EUR 34,200. Of the fees for term of office, 60 per cent would be paid in cash and 40 per cent would be used to acquire Oriola Corporation's shares for the members of the Board of Directors on the Nasdaq Helsinki Stock Exchange. The shares would be acquired within two weeks from the release of the Company's Interim Report 1 January-31 March 2026. Attendance fees would remain unchanged. The Chairman of the Board of Directors would receive an attendance fee of EUR 1,000 per meeting for meetings of the Board of Directors held in the Chairman's home country and EUR 2,000 for meetings of the Board of Directors held elsewhere and the other members of the Board of Directors would receive attendance fees of EUR 500 per meeting for meetings held in the home country of the respective member of the Board of Directors and EUR 1,000 for meetings held elsewhere. Attendance fees would correspondingly also be paid to the Chairman and members of Company committees. Travel expenses would be reimbursed in accordance with the travel policy of the Company.

12. Resolution on the number of members of the Board of Directors
The Nomination Board proposes to the Annual General Meeting that the number of members of the Board of Directors would be confirmed as seven (7).

However, should any number of the candidates proposed by the Nomination Board for any reason not be available for election to the Board of Directors, the proposed number of members shall be decreased accordingly.

13. Election of members of the Board of Directors and Chairman
The Nomination Board proposes to the Annual General Meeting that, for the next term of office, current members of the Board of Directors Petra Axdorff, Ann Carlsson Meyer, Yrjö Närhinen, Ellinor Persdotter Nilsson, Harri Pärssinen and Heikki Westerlund would be re-elected to the Board of Directors. The Nomination Board proposes to the Annual General Meeting that, for the next term of office, Pekka Pajamo would be elected as a new member of the Board of Directors.

The Nomination Board proposes to the Annual General Meeting that, for the next term of office, Heikki Westerlund would be re-elected as Chairman of the Board of Directors.

Should any of the candidates presented above for any reason not be available for election to the Board of Directors, the remaining available candidates are proposed to be elected in accordance with the proposal by the Nomination Board.

The Nomination Board has assessed all candidates to the Board of Directors to be independent of the Company and its major shareholders. All the candidates proposed have given their consent to being elected members of the Board of Directors.

With regard to the selection procedure for the members of the Board of Directors, the Nomination Board recommends that shareholders take a position on the proposal as a whole at the Annual General Meeting. The Nomination Board is responsible for ensuring that the proposed Board of Directors as a whole has sufficient expertise, knowledge and competence and that the composition of the Board of Directors takes into account the independence requirements set out in the Finnish Corporate Governance Code for listed companies and the stock exchange rules that apply to the Company.

The Nomination Board notes that the proposed composition of the Board of Directors corresponds to the requirements of the Finnish Corporate Governance Code and the diversity principles approved for the Company. When electing members of the Board of Directors, attention shall be paid to members' mutually complementary experience and competence.

The biographicals of the proposed members of the Board of Directors are presented on the Company's website at www.oriola.com.

14. Resolution on the remuneration of the auditor
In accordance with the recommendation of the Board's Audit Committee, the Board of Directors proposes to the Annual General Meeting that the fees of the Company's auditor be paid according to an invoice approved by the Company.

15. Election of the auditor
In accordance with the recommendation of the Board's Audit Committee, the Board of Directors proposes to the Annual General Meeting that Authorised Public Accountants KPMG Oy Ab, who has put forward Authorised Public Accountant Kim Järvi as principal auditor, would be re-elected as the auditor of the Company.

16. Resolution on the remuneration of the sustainability reporting assurance provider
In accordance with the recommendation of the Board's Audit Committee, the Board of Directors proposes to the Annual General Meeting that the fees of the Company's sustainability reporting assurance provider be paid according to an invoice approved by the Company.

17. Election of the sustainability reporting assurance provider
In accordance with the recommendation of the Board's Audit Committee, the Board of Directors proposes to the Annual General Meeting that Authorised Sustainability Audit Firm KPMG Oy Ab, who has put forward Kim Järvi as principal authorised sustainability auditor, would be re-elected as the sustainability reporting assurance provider of the Company.

18. Authorising the Board of Directors to decide on a share issue as well as the issuance of special rights entitling to shares
The Board of Directors proposes that the Annual General Meeting authorise the Board of Directors to decide on a share issue as well as the issuance of special rights entitling to shares pursuant to Chapter 10, Section 1 of the Finnish Companies Act in one or several tranches. This authorisation comprises the right to issue new shares or assign treasury shares held by the Company.

It is proposed that this authorisation cover a combined maximum of 18,500,000 shares of the Company, representing approximately 9.98 per cent of all shares in the Company. The new shares and treasury shares may be issued for consideration or without consideration. 

This authorisation granted to the Board of Directors includes the right to derogate from the shareholders' pre-emptive subscription right and the right to grant special rights subject to the conditions mentioned in the Finnish Companies Act. Subject to the above restrictions, this authorisation may be used i.a. to develop the capital structure of the Company and as payment of consideration when financing and executing corporate acquisitions or other business arrangements and investments or as part of the Company's incentive plans and share savings plan, however, so that the Board of Directors may issue a maximum of 1,000,000 shares to be used as a part of the Company's incentive plans and share savings plan, which corresponds to approximately 0.54 per cent of all the shares in the Company. Pursuant to this authorisation, shares held by the Company as treasury shares may also be sold through trading on the regulated market organised by Nasdaq Helsinki Ltd. 

The Board of Directors resolves on all other terms of the issuance of shares and special rights entitling to shares pursuant to Chapter 10, Section 1 of the Finnish Companies Act. This authorisation is proposed to remain in effect for a period of eighteen (18) months from the decision of the Annual General Meeting, however, at most until the beginning of the Company's next Annual General Meeting.

It is proposed that this authorisation revokes all previous share issue authorisations granted to the Board of Directors to the extent that they have not been exercised.

19. Authorising the Board of Directors to decide on the repurchase of the Company's own shares
The Board of Directors proposes that the Annual General Meeting authorise the Board of Directors to decide on the repurchase of the Company's own shares in one or several tranches on the following terms and conditions: 

According to this authorisation, the Board of Directors is entitled to decide on the repurchase of no more than 18,500,000 of the Company's own shares, which represent approximately 9.98 per cent of all shares in the Company. This authorisation may only be used in such a way that in total no more than one tenth (1/10) of all shares in the Company may at each time be in the possession of the Company and its subsidiaries.

Shares may also be repurchased in accordance with the resolution of the Board of Directors in a proportion other than that in which the shares are owned by the shareholders, using funds belonging to the Company's unrestricted equity and at a price formed in trading on regulated market on the date of the repurchase or otherwise at a price formed on the market. The Board of Directors decides how the shares will be repurchased. Among other means, derivatives may be used in the acquisition of the shares. The repurchase of the shares reduces the Company's distributable unrestricted equity.

The shares may be repurchased to develop the Company's capital structure, to execute corporate transactions or other business arrangements, to finance investments, to be used as a part of the Company's incentive schemes or to be otherwise relinquished, held by the Company, or cancelled. The authorisation also includes the right to accept the Company's own shares as a pledge.

The Board of Directors decides on all other matters related to the repurchase of shares. This authorisation to repurchase the Company's own shares shall remain in force for a period of not more than eighteen (18) months from the resolution of the Annual General Meeting, however, at most until the beginning of the Company's next Annual General Meeting.

This authorisation revokes the authorisation granted to the Board of Directors by the Annual General Meeting on 2 April 2025 in respect of the repurchase of the Company's own shares to the extent that the Board of Directors has not previously resolved to repurchase shares based on such authorisation.

20. Closing of the Annual General Meeting

B. Documents of the Annual General Meeting
The proposals of the Board of Directors and the Nomination Board to the Annual General Meeting, as well as this notice and the organisational document of the Annual General Meeting are available on Oriola's website at www.oriola.com. The financial statements, the report of the Board of Directors (including the sustainability statement), the auditor's report, the sustainability reporting assurance report and the remuneration report of Oriola will be available on the above-mentioned website no later than 4 March 2026. The proposals for decisions and the other documents mentioned above will also be available at the Annual General Meeting and copies of these documents and this notice will be sent to shareholders upon request. The minutes of the Annual General Meeting will be published on the Company's website on 8 April 2026 at the latest.

C. Instructions for the Participants of the Annual General Meeting
1. Shareholder registered in the shareholders' register
Each shareholder who is registered in the shareholders' register of the Company held by Euroclear Finland Oy on the record date of the Annual General Meeting, i.e. Friday, 13 March 2026, has the right to participate in the Annual General Meeting. A shareholder whose shares are registered on their personal Finnish book-entry account, including an equity savings account, is registered in the shareholders' register of the Company. 

A shareholder, who is registered in the shareholders' register of the Company and who wants to participate in the Annual General Meeting, has to register for the meeting no later than on Friday 20 March 2026 at 10:00 a.m. (EET) by giving a prior notice of participation. The notice must be received before the end of the registration period. Registration for the Annual General Meeting will commence on Wednesday, 25 February 2026 at 12:00 noon (EET). Notice of participation to the Annual General Meeting can be given: 

a) Through the Company's website at www.oriola.com/agm-2026

Online registration requires that the shareholder or their legal representative or proxy representative use strong electronic authentication either by Finnish, Swedish or Danish banking codes or mobile certificate.

b) By mail to the address Innovatics Ltd, AGM/Oriola Corporation, Ratamestarinkatu 13 A, FI-00520 Helsinki, Finland or by email to the address agm@innovatics.fi. 

c) By phone to number +358 10 2818 909 (from Monday to Friday 9:00 a.m. to 12:00 noon and 1:00 p.m. to 4:00 p.m. (EET)). 

When registering by phone, a shareholder cannot vote in advance.

In connection with the registration, a shareholder shall notify, their name, date of birth or business ID, address, telephone number and e-mail address and the name of a proxy representative, legal representative or assistant, if any, and the date of birth, phone number and/or e-mail of the proxy representative, legal representative or assistant, as applicable. The personal data given by the shareholders to Oriola or Innovatics Ltd is used only in connection with the Annual General Meeting and with the processing of necessary related registrations.

The shareholder, their proxy representative, legal representative or assistant shall, if necessary, be able to prove their identity and/or right of representation at the meeting venue.

Additional information on registration and advance voting is available by phone during the registration period of the Annual General Meeting at Innovatics Ltd's phone number +358 10 2818 909 from Monday to Friday 9:00 a.m. to 12:00 noon and 1:00 p.m. to 4:00 p.m (EET).

For further information on how Oriola processes personal data, please review Oriola's privacy notice regarding the Annual General Meeting, which is available at the Company's website at www.oriola.com. Shareholders are asked to note that in connection with registration and advance voting by email the registrant submits personal data by a possibly unsecure connection on their own responsibility.

2. Holder of nominee-registered shares
A holder of nominee-registered shares has the right to participate in the Annual General Meeting by virtue of such shares based on which the holder would be entitled, on the record date of the Annual General Meeting, i.e. Friday, 13 March 2026, to be registered in the shareholders' register of the Company held by Euroclear Finland Oy. Participation requires, in addition, that the shareholder on the basis of such shares has been temporarily registered in the shareholders' register held by Euroclear Finland Oy at the latest by Friday, 20 March 2026 at 10:00 a.m. (EET). As regards nominee-registered shares, this constitutes due registration for the Annual General Meeting.

A holder of nominee-registered shares is advised to well in advance request necessary instructions regarding the temporary registration in the Company's shareholders' register, the issuing of proxy documents and voting instructions and registration for the Annual General Meeting as well as voting in advance from their custodian bank. The account management organisation of the custodian bank must register a holder of nominee-registered shares, who wishes to participate in the Annual General Meeting, temporarily in the shareholders' register of the Company within the registration period applicable to holders of nominee-registered shares and take care of the voting in advance on behalf of the holder of nominee-registered shares before the expiry of the registration period applicable to holders of nominee-registered shares.

3. Proxy representatives and powers of attorney
A shareholder may participate in the Annual General Meeting and exercise their rights at the meeting by way of proxy representation. Proxy representatives may also vote in advance in the manner described in this notice.

A proxy representative must identify themself in the electronic registration service and advance voting in person with strong identification, after which they can register and vote in advance on behalf of the shareholder they represent. A proxy representative shall produce a dated proxy document or otherwise in a reliable manner demonstrate their right to represent the shareholder at the Annual General Meeting. If a shareholder participates in the Annual General Meeting by means of several proxy representatives representing the shareholder with shares at different securities accounts, including equity savings accounts, the shares by which each proxy representative represents the shareholder shall be identified in connection with the registration for the Annual General Meeting. 

Proxy and voting instruction templates will be available on the Company's website at www.oriola.com from 25 February 2026 onwards. Possible proxy documents shall be delivered as an attachment in connection with the electronic registration, by regular mail to the address Innovatics Ltd, AGM/Oriola Corporation, Ratamestarinkatu 13 A, FI-00520 Helsinki, Finland or by email to the address agm@innovatics.fi before 20 March 2026 at 10:00 a.m. (EET) by which time the proxy documents must be received.

In addition to providing proxy documents, the shareholder or their proxy representative must take care of registering for the Annual General Meeting in the manner described above in this notice.

Shareholders can also use electronic authorisation services of Suomi.fi instead of a traditional proxy document, after which the representative can register and vote in advance on behalf of the shareholder they represent. In that case the person authorises a named authorised person through Suomi.fi's services at www.suomi.fi/e-authorizations by using the mandate theme "Representation at the General Meeting". In connection with the registration, Annual General Meeting services require strong electronic authentication after which the electronic authorisation is automatically verified. Strong electronic authentication works with banking codes or a mobile certificate. For more information, please see Suomi.fi's e-authorisation pages at www.suomi.fi/e-authorizations and the Company's website www.oriola.com.

4. Voting in advance
A shareholder whose shares are registered on their personal Finnish book-entry account, including an equity savings account, may vote in advance during the period from 25 February 2026 at 12:00 noon (EET) until 20 March 2026 at 10:00 a.m. (EET) on certain matters on the agenda of the Annual General Meeting in the following ways: 

a) Through the Company's website at www.oriola.com/agm-2026

Electronic advance voting requires that the shareholder or their legal representative or proxy representative use strong electronic authentication either by Finnish, Swedish or Danish banking codes or mobile certificate.

b) By mail or email 

A shareholder can deliver the advance voting form available on the Company's website at www.oriola.com or corresponding information by mail to Innovatics Ltd to the address Innovatics Ltd, AGM/Oriola Corporation, Ratamestarinkatu 13 A, FI-00520 Helsinki, Finland or by email to the address agm@innovatics.fi. The advance votes shall be received before the expiry of the advance voting period. The advance voting form will be available on the Company's website 25 February 2026 at the latest.

Submitting votes in such manner before the expiry of the registration and advance voting period constitutes due registration for the Annual General Meeting, provided that the documents delivered by the shareholder contain the information required for registration.

A shareholder who has voted in advance cannot use their right to request information under the Finnish Companies Act or their right to request a vote nor change the given votes unless the shareholder participates in the Annual General Meeting in person or by way of proxy representation at the meeting venue.

For holders of nominee-registered shares, advance voting is carried out via the account manager. The account manager may vote in advance on behalf of the holders of nominee-registered shares they represent in accordance with the voting instructions provided by the holders of nominee-registered shares during the registration period for the nominee-registered shares.

An agenda item subject to advance voting is considered to have been presented unchanged to the Annual General Meeting. The terms and conditions as well as other instructions related to the advance voting are also available on the Company's website at www.oriola.com.

5. Other information
The meeting can be followed online via a webcast. Instructions on following the webcast will be available on the Company's website at www.oriola.com. Following the meeting via webcast is not considered participating in the Annual General Meeting or exercising of shareholders' rights.

Pursuant to Chapter 5, Section 25 of the Finnish Companies Act, a shareholder who is present at the Annual General Meeting has the right to ask questions and request information with respect to the matters to be considered at the meeting.

Changes in shareholding after the record date of the Annual General Meeting do not affect the right to participate in the Annual General Meeting or the number of votes held by the shareholder.

On the date of the notice to the Annual General Meeting, i.e. 25 February 2026, the Company has in total 185,325,378 shares registered in the Trade Register, whose total number of votes is 185,325,378. The Company has in total 80,258 Company's own treasury shares by which voting rights cannot be exercised at the Annual General Meeting. The Company's own treasury shares held by the Company represent 0.04 per cent of all the shares and votes in the Company.

Espoo, 25 February 2026

Oriola Corporation
Board of Directors

Petter Sandström
General Counsel

Distribution:
Nasdaq Helsinki Ltd
Key media

Released by:
Oriola Corporation
Corporate Communications
Orionintie 5
FI-02200 Espoo
www.oriola.com
 

Oriola Corporation Stock Exchange Release 25 February 2026 at 8.30 a.m. EET

Oriola Corporation's Financial Statements Release 1 January-31 December 2025

Steady progress in adjusted EBITDA and strategic priorities

October-December 2025 highlights

• Invoicing increased by 12.8 % to EUR 1,109.8 (983.5) million.
• Net sales increased by 13.9% to EUR 502.0 (440.7) million.
• Sales margin increased by 2.0% to EUR 43.3 (42.4) million.
• Adjusted EBITDA was EUR 9.9 (9.4) million.
• EBITDA was EUR 5.8 (7.0) million including adjusting items of EUR -4.1 (-2.4) million.
• Result for the quarter totalled EUR -18.0 (-17.8) million and earnings per share were EUR -0.10 (-0.10). The loss includes Oriola share of the result of the joint venture Kronans Apotek of EUR -18.9 (-19.5) million, which includes Oriola's share of the goodwill impairment EUR 15.8 (16.3) million.
• Free cash flow was EUR 46.8 (39.2) million.

January-December 2025 highlights:

• Invoicing increased by 11.4 % to EUR 4,201.2 (3,771.8) million.
• Net sales increased by 13.5% to EUR 1,906.2 (1,679.7) million.
• Sales margin increased by 4.4% to EUR 166.8 (159.8) million.
• Adjusted EBITDA was EUR 35.1 (33.4) million.
• EBITDA was EUR 20.3 (27.2) million including adjusting items of EUR -14.8 (-6.2) million. 
• Result for the financial year totalled EUR -27.2 (-20.1) million and earnings per share were EUR -0.15 (-0.11). The loss includes Oriola share of the result of the joint venture Kronans Apotek of EUR -22.8 (-24.8) million, which includes Oriola's share of the goodwill impairment EUR 15.8 (16.3) million.
• Free cash flow was EUR 58.4 (43.4) million.

The Board of Directors proposes to the Annual General Meeting that a dividend of EUR 0.03 (0.07) per share be paid for 2025. It is further proposed that the Annual General Meeting authorises the Board of Directors, at its discretion, to resolve on the distribution of a possible second dividend instalment up to a maximum of EUR 0.04 per share. It is the intention of the Board of Directors that the possible dividend payment pursuant to this authorisation would be carried out in November 2026.

Key figures

¹ Adjusting items are specified in Adjusting items on page 19.

In order to reflect the underlying business performance and to enhance comparability between financial periods, Oriola discloses certain performance measures of historical performance, financial position and cash flows, as permitted in the "Alternative performance measures" guidance issued by the European Securities and Markets Authority (ESMA). These measures should not be considered as a substitute for measures of performance in accordance with the IFRS. The calculation methods of these measures are provided under Key financial indicators in this Interim report.

Outlook for 2026
In 2026, the pharmaceutical distribution market is expected to continue to grow. Value growth is expected to be driven by high-value pharmaceuticals and products requiring advanced logistics.

The uncertainty in the geopolitical environment remains, and the availability issues of certain pharmaceuticals are expected to continue. Typically, in economic uncertainty, consumers tend to shift purchases of everyday health and wellness products toward low-price categories. 

For 2026, Oriola expects the adjusted EBITDA to increase from the previous year (2025: EUR 35.1 million). The expectation of improved adjusted EBITDA is based on growing markets and strategy execution.

CEO Katarina Gabrielson:
We delivered steady progress in line with our expectations, and the second half of the year was particularly strong. Throughout the year, we reinforced customer focus - a strategic priority following the introduction of our new operating model. Strengthening partnerships, onboarding new customers, expanding our value-adding services and product portfolio, and improving operational efficiency all contributed to a solid year and a stronger foundation for the next phase of our strategy. In 2025, Oriola's net sales increased by 14% to EUR 1,906 million. Sales margin improved to EUR 166.8 (159.8) million and adjusted EBITDA grew to EUR 35.1 million, exceeding the previous year's level.

Sustainability remained a key priority in 2025. Our new ambitious climate targets were validated by the Science Based Targets initiative (SBTi), confirming alignment with the 1.5°C pathway. Compared with the 2023 base year, we have reduced Scope 1 and Scope 2 emissions by 40%.

Progress with strategic investments
We also advanced our strategic investment to renew Oriola's ERP (enterprise resource planning) and WMS (warehouse management systems). At the end of the year, we completed the first deployment in Sweden, and preparations for the next deployment are underway. The planning phase for the distribution operations in Finland was finalised in December, and in early January 2026, the Board of Directors approved the development of a highly automated, state-of-the-art distribution centre in Järvenpää, valued at EUR 110-120 million. The distribution centre will increase capacity by 30% and cold chain capacity by 80%. Built to BREEAM Excellent standards, it will be 50% more energy efficient and reduce Scope 1 and 2 emissions in Finland. Construction has already started, with relocation planned to begin in late 2027. Following this move, our headquarters will relocate to another site within Espoo.

Stronger supply chain
During the year, we strengthened Oriola's supply chain, ensuring stable and reliable distribution services for our customers. In Sweden, we expanded capacity to support strong volume growth and secure product availability. We also delivered our most successful vaccine season, with delivered volumes exceeding the previous year by more than 20%. Continuous improvement efforts increased tote filling rates in both countries enhancing transport efficiency and sustainability. We also implemented new digital and AI-driven tools that improve workflow and productivity.

Improved customer satisfaction
In the distribution business, we emphasised strong partnerships and engaged in closer dialogues with our customers, implementing improvement measures in response to their feedback. This is evidenced by a continuous improvement of customer satisfaction, reflected in an all-time high Net Promoter Score (NPS). With our holistic service offering and strong market support we aim to reduce complexity for our customers.

Solid portfolio meeting customer needs
We continued to expand our wholesale offering based on customer needs, secured new listings, and renewed our own brands such as Dexal and Apteekkarin. These efforts are visible in improved NPS results, particularly in feedback regarding our range and quality of products. We also developed capabilities to serve cross-market the growing e-commerce and retail customer base, for example through pallet deliveries in Sweden. In advisory, we have identified business opportunities to use AI-driven tools to enhance our services, including commercial data and medical information.

Acquisition to strengthen advisory business
During the first half of the year, we completed the sale of the Swedish dose dispensing business and acquired MedInfo in Denmark. The acquisition strengthens our position in the Nordic advisory market and enables us to offer a full-service portfolio in medical information and patient support programmes in all Nordic markets.

Q4 2025: Good progress in both segments
In the fourth quarter, net sales increased by 14% to EUR 502 million and sales margin reached EUR 43.3 (42.4) million, both supported by the Distribution and Wholesale segments. Adjusted EBITDA increased to EUR 9.9 (9.4) million. The Distribution segment continued to deliver solid results in the fourth quarter, driven by strong partnerships, increase in value-adding services, higher vaccine volumes in Sweden, and market value growth. In Finland, the dose dispensing business performed well. Within the Wholesale segment, the investments to strengthen our commercial capabilities in Finland at the beginning of the year started to show good results in the fourth quarter. In addition, growth in Finland was supported by special-licensed medicines and double-digit growth in sales to veterinarians. Parallel import in Sweden continued a strong performance driven by weight-loss medicines. In advisory, the positive development in commercial data services continued with strong growth.

Integration of Kronans Apotek completed
Our joint venture, Kronans Apotek, achieved transformation milestones in 2025, completing its integration and harmonising key business systems. Activities included pharmacy network adjustments and private label initiatives. These efforts strengthened the organisation's governance and operational foundation, and improved scalability. Throughout 2025, multiple commercial initiatives were started, and the organisation defined its long-term commercial strategy. In addition, actions were started to strengthen cross-functional coordination, to increase flexibility and competitiveness, and to optimise key processes and customer journeys. In the fourth quarter, Kronans Apotek reported a market share of 20.7% and total sales increased in local currency by 2.9% from the previous year, driven by growth in both physical pharmacies and the e-commerce channel.

Commitment to customer focus and strategic priorities
Looking ahead, we have initiated a review of Oriola's long-term plan and financial targets to support growth, drive profitability, and establish capital allocation priorities. We will share details of the review at our Capital Markets Day on 12 May 2026, in Helsinki.

Our commitment to our customers remains strong. We will continue to develop our holistic services and product offering, while executing our strategic priorities essential for our long-term growth and success. These initiatives require effective change management, strong leadership, and continuous open dialogue with our people.

In the beginning of the year, we strengthened the commercial capabilities within our management team, enhancing our ability to capture new opportunities and supporting the company's continued growth. The progress achieved in 2025 gives us confidence that our strategy is working, and we enter the coming year well positioned to build further on this achievement.

I want to thank everyone at Oriola for our joint achievements and the dedication over the past year. Your hard work and commitment have been instrumental to our progress. I also extend my appreciation to our customers, partners and shareholders for their ongoing support and trust in us.

Disclosure procedure
This stock exchange release is a summary of Oriola Corporation's Financial Statements Release 2025. The complete report is attached to this release in pdf format and is also available on Oriola's website at www.oriola.com.

Analyst and investor meeting at 10.00 a.m. EET
Oriola's CEO Katarina Gabrielson and CFO Mats Danielsson will present the full-year results at a live audiocast meeting today at 10.00 a.m. EET. Join the meeting: https://oriola.events.inderes.com/q4-2025  

Next financial reports
Oriola Corporation will publish its Annual Report 2025 during week 10 (latest 4 March 2026) and the Interim Report for January-March 2026 on Wednesday 29 April 2026.

Oriola's Capital Markets Day 2026
The Capital Markets Day will be held on 12 May 2026 live in Helsinki and webcasted online. Detailed information on the agenda, venue and registration will be published closer to the event.

Further information:
Mats Danielsson
CFO
email: mats.danielsson@oriola.com

Mikael Wegmüller
VP, Communications and Sustainability
email: mikael.wegmuller@oriola.com

Distribution:
Nasdaq Helsinki Ltd
Key media

Oriola Corporation  Investor news  11 February 2026 at 9:00 a.m. EET

Oriola Corporation to publish its Financial Statements Release 2025 on 25 February 2026

Oriola Corporation will publish its Financial Statements Release 2025 on Wednesday 25 February 2026 at around 8:30 a.m. EET. The Financial Statements Release will be available on Oriola's website after the publication.

Welcome to join our results presentation

CEO Katarina Gabrielson and CFO Mats Danielsson will present the full-year results at an audiocast meeting on the same day starting at 10.00 a.m. EET. The link to the webcast will be available on Oriola's website: https://www.oriola.com/investors/.

Q&A

Questions to the management can be presented through the audiocast chat.

Presentation material and recording

The presentation material and a recording of the audiocast will be available on Oriola's website: https://www.oriola.com/investors/reports-and-presentations/

Oriola Corporation

Further information:

Tua Stenius-Örnhjelm, Investor Relations
tel. +358 407488864
investor.relations@oriola.com

Oriola Corporation Stock Exchange Release 15 January 2026 at 10:00 a.m. EET

Proposals of the Shareholders' Nomination Board of Oriola Corporation concerning the Board of Directors to be elected by the 2026 Annual General Meeting

Oriola's Shareholders' Nomination Board presents its proposal to the 2026 Annual General Meeting concerning the composition of the Board of Directors as follows:

• The number of members of the Board of Directors would be seven; however, if any of the proposed members becomes unavailable prior to the Annual General Meeting, the maximum number of elected Board members shall be the number of proposed members available
• The current members of the Board of Directors Petra Axdorff, Ann Carlsson Meyer, Yrjö Närhinen, Ellinor Persdotter Nilsson, Harri Pärssinen and Heikki Westerlund would be re-elected.
• Pekka Pajamo would be elected new member of the Board of Directors
• Heikki Westerlund would be re-elected Chairman of the Board of Directors

The Nomination Board has assessed all candidates to the Board of Directors to be independent of the company and its major shareholders. All the candidates proposed have given their consent to being elected members of the Board of Directors.

With regard to the selection procedure for the members of the Board of Directors, the Shareholders' Nomination Board recommends that shareholders take a position on the proposal as a whole at the General Meeting. The Shareholders' Nomination Board is responsible for ensuring that the proposed Board of Directors as a whole has sufficient expertise, knowledge and competence and that the composition of the Board of Directors takes into account the independence requirements set out in the Finnish Corporate Governance Code for listed companies and the stock exchange rules that apply to the company.

The Nomination Board notes that the proposed Board composition corresponds to the requirements of the Finnish Corporate Governance Code and the diversity principles approved for the company. When electing Board members, attention shall be paid to members' mutually complementary experience and competence.

The Nomination Board also proposes to the 2026 Annual General Meeting that the remunerations would be paid to the members of the Board of Directors as follows:

• Chairman of the Board: fee for term of office of 71,400 euros (2025: 71,400 euros)
• Vice chairman of the Board: fee for term of office of 40,800 euros (2025: 40,800 euros)
• Chairman of a Board Committee (provided that person is not the Chairman or Vice chairman of the Board): fee for term of office of 40,800 euros (2025: 40,800 euros)
• Other members of the Board: fee for term of office of 34,200 euros (2025: 34,200 euros)
• Attendance fees would remain unchanged and be paid as follows:
  • for Board of Directors meetings 1,000 euros per meeting to the Chairman for meetings held in the Chairman's home country and 2,000 euros for meetings held elsewhere
  • 500 euros per meeting to other members of the Board for meetings held in the home country of the respective member and 1,000 euros for meetings held elsewhere
  • for committee meetings 1,000 euros per meeting to the committee Chairman for meetings held in the Chairman's home country and 2,000 euros for meetings held elsewhere and
  • 500 euros per meeting to committee members for meetings held in the home country of the respective committee member and 1,000 euros for meetings held elsewhere.
• Of the fees for term of office, 40 per cent would be paid in Oriola Corporation's shares and 60 per cent would be paid in cash, so that the Oriola Corporation's shares would be acquired for the Board members on the Nasdaq Helsinki Stock Exchange within two weeks from the release of the Interim Report 1 January-31 March 2026 of the company.
• Travel expenses would be reimbursed in accordance with the travel policy of the company

The Board of Directors of Oriola will include these proposals of the Nomination Board in the notice of the 2026 Annual General Meeting.

It is noted that Pekka Pajamo has resigned from Oriola's Shareholders' Nomination Board and has not participated in the final assessment process made by the Nomination Board, nor has he participated in the preparation of the proposals of the Shareholders' Nomination Board. In accordance with the rules of procedure of the Oriola's Shareholders' Nomination Board the Nomination Board has continued its work in a composition of four members consisting of: Peter Immonen (Chairman of the Board of Directors of WIP Asset Management Oy, member of the Board of Directors of Mariatorp Oy and Wipunen varainhallinta Oy) as acting chairman, Annika Ekman (Chief Investment Officer, Ilmarinen Mutual Pension Insurance Company), Jari Paloniemi (M.Sc. [Economics]) and Jukka Ylppö (M.Sc. [Technology] and M.Sc. [Economics]). Heikki Westerlund, Chairman of the Board of Directors of Oriola, has participated in the work of the Nomination Board as an invited expert.

Presentation of Pekka Pajamo:

Pekka Pajamo (b. 1962, Finnish citizen, M.Sc. [Econ.]) has served as Senior Vice-President, Finance and Internal Services of Varma Mutual Pension Insurance Company since 2012. Prior to this Pajamo was employed by KPMG Oy AB 1988-2012, as Authorised Public Accountant 1993-2012 and Partner 1998-2012. Pajamo currently serves as member of the board of the Finnish National Gallery, Leino Group and the Ida Aalberg Foundation.

Oriola Corporation

Further information:

Peter Immonen
Acting Chairman of the Shareholders' Nomination Board
e-mail: peter.immonen@wip.fi

Petter Sandström
General Counsel, secretary to the Board of Directors
tel. +358 10 429 5761
e-mail: petter.sandstrom@oriola.com

Distribution:
Nasdaq Helsinki Ltd
Key media

Oriola Corporation Stock Exchange Release 7 January 2026 at 12:35 p.m. EET

Inside information: Oriola accelerates growth and modernises Finnish operations with a highly automated, state-of-the-art distribution centre in Järvenpää

Oriola has completed the planning phase for its distribution operations and has resolved on the development of a highly automated, state-of-the-art distribution centre located in Järvenpää, Finland, in total valued at EUR 110-120 million. The investment will be financed in a capital-efficient way through a long-term lease arrangement for the building, machinery and equipment, while the land is acquired and owned by Oriola. The new distribution centre will be financed by SEB Leasing Oy. Construction of this facility is scheduled to commence in the first quarter of 2026, with the relocation of operations from Espoo to Järvenpää anticipated to start by the end of 2027. Additionally, Oriola's headquarters will be relocated within Espoo.

The investment is anticipated to yield returns through enhanced operational efficiency, expanded capacity, and value generated from the eventual redevelopment of the current Espoo site. The lease arrangement will ensure outgoing cash flow to match incoming flows in an optimal way. During the relocation, both Espoo and Järvenpää sites will simultaneously be operational for a limited period, which will have an impact on cost. The investment will therefore have limited impact on cash flow and profitability before the new site is taken into use.

"The Järvenpää distribution centre is a major milestone in Oriola's long-term strategic plan to modernise operations and enable future growth. Through state-of-the-art, scalable and highly automated logistics, the facility directly supports our growth ambitions and is a step towards improved profitability in Finland. Together with the ongoing ERP and warehouse management initiative, the new distribution centre helps us to reach our financial targets and strengthen our competitiveness for the long term. These modernisations enable us to serve our customers even better by offering advanced logistics solutions to meet their evolving needs", says Oriola's CEO Katarina Gabrielson.

With an optimal distribution location in Southern Finland and building area of approximately 30,000 square metres, this strategic investment strengthens Oriola's logistics capabilities in response to market demands, ability to meet evolving customer and market requirements, drive future growth, and improve profitability. The previously announced change negotiations relating to the plans to build a new distribution centre have also now been concluded. No redundancies were made as all current logistics personnel will be offered the possibility to relocate to new distribution site. Customer operations will continue without disruptions during the relocation.

Järvenpää was selected for its optimal location, accessibility, and suitability for large-scale logistics. The Järvenpää centre supports Oriola's sustainability ambitions and further strengthens Oriola's position as part of Finland's critical healthcare infrastructure, ensuring reliable pharmaceutical distribution for society. The investment is expected to boost operational efficiency through automation and optimised layout. In addition, the new distribution centre offers 30% more capacity, including 80% added capacity to handle cold chain products. The building is planned to be constructed to BREEAM Excellent-level standards, and it will be 50% more energy efficient and reduce Oriola's Scope 1 and 2 CO₂ emissions in Finland.

The relocation of the distribution centre to Järvenpää will give an opportunity to redevelop the owned land area in Espoo, Finland, valued in Oriola's balance sheet at EUR 0.1 million. The area is subject to changes in planning and zoning as Oriola has filed an application to have the area re-zoned to allow also residential building. The redevelopment of the current land area is expected to release capital after the completion of the relocation of the distribution operations.

Invitation to management presentation

Analysts, investors and media are invited to join a Microsoft Teams call where Oriola's management will talk through and answer questions on the new distribution centre. The call will take place on Wednesday 7 January 2026 at 3:00 p.m. EET. Click here to join the call.

Further information:

Katarina Gabrielson
CEO
tel. +46 72 234 8809
email: katarina.gabrielson@oriola.com

Mikael Wegmüller
VP, Communications and Sustainability
tel. +356 40 7762 314
email: mikael.wegmuller@oriola.com

Distribution:

Nasdaq Helsinki Ltd.
Key media

Oriola Corporation Investor news 7 January 2026 at 12:30 p.m. EET

Oriola initiates review of long-term plan, financial targets and capital allocation priorities - Capital Markets Day scheduled

Following the completion of its strategy review, Oriola is conducting an analysis of its full potential. As a result, Oriola is further advancing and clarifying its long-term plan, to support growth and drive profitability, and establishing capital allocation priorities to enhance shareholder value creation.

Oriola aims to complete the review of the long-term plan, financial targets and capital allocation priorities during spring 2026, and share details at its Capital Markets Day on 12 May 2026. Oriola's long-term plan and capital allocation priorities will focus on following key topics:

• Responding to evolving market needs and growing customer requirements
• Accelerating growth and improving profitability
• Maintaining strong cash generation and allocating a reasonable share of net operating cash flow to growth-oriented investments in core businesses
• Initiating a balance sheet optimisation programme including an evaluation of the divestment of non-core assets
• Strengthening and then maintaining reasonable equity level to ensure financial resilience
• Revisiting financial targets and dividend policy to align with renewed strategic ambitions
• Actively utilising the AGM authorisation to do share buybacks

These initiatives will provide a clear framework for disciplined investments, growth priorities, cash flow management, and shareholder returns, ensuring Oriola is well-positioned for the next phase of its strategic journey.

"Over the past year, we achieved good progress while strengthening customer relationships and attracting new ones. During the next 3-5 years we are taking steps to shape the company's future, focusing on building a stronger foundation for sustainable growth and profitability while continuing to deliver value for our shareholders and customers. As we advance our long-term plan, we remain fully committed to serving our customers and executing our current plans," says Oriola's CEO Katarina Gabrielson.

Save-the-date: Oriola's Capital Markets Day 2026

The Capital Markets Day will be held on 12 May 2026 live in Helsinki and webcasted online. Detailed information on the agenda, venue and registration will be published closer to the event.

Further information:

Katarina Gabrielson
CEO
tel. +46 72 234 8809
email: katarina.gabrielson@oriola.com 

Mikael Wegmüller
VP, Communications and Sustainability
tel. +356 40 7762 314
email: mikael.wegmuller@oriola.com

Oriola Corporation  Stock Exchange Release  19 December 2025 at 1:00 p.m. EET

Kronans Apotek to record an impairment with an impact of approximately EUR 16 million to Oriola's net result

The integration in Oriola's joint venture company Kronans Apotek and the transition to one ERP system have been completed during this year, however both have required more time than expected. Due to this, Kronans Apotek will record a goodwill impairment of approximately SEK 349 million in its fourth quarter results.

Oriola's share of the impairment is approximately SEK 175 million or approximately EUR 16 million and will be recorded in the share of results in joint venture in the fourth quarter.

The value of Oriola's investment in Kronans Apotek after the impairment totals approximately EUR 187 million. The impairment will not affect the distributable funds of the parent company, Oriola Corporation.

The impairment will be recorded in Oriola's fourth quarter 2025 results and will have no effect on the Group's cash flow or adjusted EBITDA. Oriola's outlook for 2025 remains unchanged. Oriola will publish its Financial Statements Release for 2025 on 25 February 2026.

Further information:

Mats Danielsson
CFO
tel. +358 50 394 8575
email: mats.danielsson@oriola.com

Mikael Wegmüller
VP, Communications and Sustainability
tel. +356 40 7762 314
email: mikael.wegmuller@oriola.com

Distribution:

Nasdaq Helsinki Ltd.
Key media

Oriola Corporation Investor news 15 December 2025 at 1 p.m. EET

Change negotiations in connection with Oriola's plan for a new distribution centre in Finland have been concluded

As part of Oriola's strategic plan to build a new distribution centre in Järvenpää, Finland, change negotiations have been concluded in good collaboration.

Oriola plans to relocate its logistics operations from the distribution centre and satellite warehouse currently in Espoo to a new facility in Järvenpää. Additionally, the company intends to move its headquarters to a new location within Espoo.

The change negotiations encompassed the entire personnel in Espoo, approximately 400 employees. No redundancies were considered during the process. The negotiations began on 24 November 2025 (see Oriola's investor news published on 17 November 2025).

Further information:
Mikael Wegmüller, VP, Communications and Sustainability
tel. +356 40 7762 314
email: mikael.wegmuller@oriola.com

Distribution:
Nasdaq Helsinki Ltd.
Key media

Oriola Corporation Investor news 17 November 2025 at 9 a.m. EET

Oriola initiates change negotiations in connection with plans for a new distribution centre in Finland

As previously communicated, one of Oriola's strategic goals focuses on driving future growth, enabled by enhanced warehouse capacity and efficiency through investments in infrastructure and technology. Oriola is planning a new distribution centre in Järvenpää, Finland. As part of Oriola's strategic evaluation process regarding a new distribution centre, the company initiates change negotiations.

This strategic initiative would strengthen Oriola's logistics capabilities to better respond to evolving market needs and growing customer requirements. It is intended to enhance operational efficiency and contribute to improved profitability. The planned new facility is expected to play a key role in supporting Oriola's long-term growth strategy while significantly contributing to its sustainability ambitions through energy-efficient design and reduced environmental impact.

The intention would be to relocate Oriola's logistics operations from the distribution centre and satellite warehouse currently in Espoo to a new facility in Järvenpää. Additionally, the plan would be to move the company's headquarters to a new location within Espoo.

Oriola initiates change negotiations that will encompass the entire personnel in Espoo, approximately 400 employees. Redundancies are not contemplated in connection with the planned changes.

The negotiations will begin on 24 November 2025.

Further information:

Katarina Gabrielson
CEO
tel. +46 72 234 8809
email: katarina.gabrielson@oriola.com

Mikael Wegmüller
VP, Communications and Sustainability
tel. +356 40 7762 314
email: mikael.wegmuller@oriola.com

Distribution:
Nasdaq Helsinki Ltd.
Key media

Oriola Corporation Stock Exchange Release 30 October 2025 at 8.30 a.m. EET

Oriola Corporation's Interim Report January-September 2025

Sales margin growth and improved adjusted EBITDA

July-September 2025 financial highlights

• Invoicing increased by 9.8 % to EUR 1,018.6 (927.7) million.
• Net sales increased by 9.2% to EUR 463.3 (424.4) million.
• Sales margin increased by 6.3% to EUR 40.0 (37.7) million.
• Adjusted EBITDA was EUR 9.6 (8.4) million.
• EBITDA was EUR 7.0 (4.9) million including adjusting items of EUR -2.6 (-3.5) million.
• Profit for the period totalled EUR 1.7 (-1.9) million and earnings per share were EUR 0.01 (-0.01).
• Free cash flow was EUR -9.2 (-3.9) million.

January-September 2025 financial highlights

• Invoicing increased by 10.9% to EUR 3,091.4 (2,788.3) million.
• Net sales increased by 13.3% to EUR 1,404.2 (1,239.0) million.
• Sales margin increased by 5.3% to EUR 123.6 (117.3) million.
• Adjusted EBITDA was EUR 25.2 (24.1) million.
• EBITDA was EUR 14.5 (20.2) million including adjusting items of EUR -10.7 (-3.9) million.  
• Profit for the period totalled EUR -9.3 (-2.3) million and earnings per share were EUR -0.05 (-0.01).
• Free cash flow was EUR 11.6 (4.2) million.

1 Adjusting items are specified in note Adjusting items on page 18.

In order to reflect the underlying business performance and to enhance comparability between financial periods, Oriola discloses certain performance measures of historical performance, financial position and cash flows, as permitted in the "Alternative performance measures" guidance issued by the European Securities and Markets Authority (ESMA). These measures should not be considered as a substitute for measures of performance in accordance with the IFRS. The calculation methods of these measures are provided under Key financial indicators in this Interim report.

Outlook for 2025

In 2025, the pharmaceutical distribution market is expected to continue to grow. Value growth is expected to be driven by high-value pharmaceuticals and products requiring advanced logistics. The uncertainty in the geopolitical environment remains, and the availability issues of certain pharmaceuticals are expected to continue.

Consumer confidence is expected to remain weak, which may have an impact on the wholesale market. Typically in economic uncertainty, consumers tend to shift purchases to low-price categories.

For 2025, Oriola expects the adjusted EBITDA to increase from the previous year (2024: EUR 33.4 million). The expectation of improved adjusted EBITDA is based on growing markets and strategy execution.

From the start of 2025, Oriola introduced adjusted EBITDA (earnings before interest, taxes, depreciation and amortisation) as a new alternative performance measure. EBITDA is widely used by management and investors when assessing the profitability of a company and cash flow generation.

CEO Katarina Gabrielson:

I am pleased with our third-quarter results. They confirm that we are on the right strategic path towards becoming the leading specialist in the wholesale of pharmaceuticals and health products.

We delivered solid results in the third quarter, with growth in both net sales and sales margin, and a year-on-year improvement in adjusted EBITDA. Our distribution business continued to perform strongly and steadily regardless the operating environment, where consumer confidence was still weak due to the overall uncertainty. The pharmaceutical distribution market in Sweden showed growth, while the Finnish market was weaker.

In the third quarter, net sales increased by 9% to EUR 463 million, and the sales margin reached EUR 40.0 (37.7) million, both driven by the Distribution and Wholesale segments. Adjusted EBITDA increased to EUR 9.6 (8.4) million. Although earlier vaccine deliveries led to high volumes and increased operating expenses towards the end of the quarter, our supply chain operations remained stable thanks to strategic initiatives implemented. For instance, we have expanded our warehousing capacity.

In the Distribution segment, net sales increased by 6% to EUR 373 million, driven by volume growth across both our existing portfolio and new customer accounts. Earlier vaccine deliveries compared to the previous year and overall market growth also contributed. Operating expenses increased mainly due to high volumes, including the need for additional warehouse capacity, and increased personnel costs. Despite the higher cost level, adjusted EBITDA increased to EUR 8.4 (7.1) million. Our strategic focus to build strong partnerships has brought good results - customer satisfaction has continued to improve and we have successfully retained all existing accounts. We are actively pursuing new business opportunities, with several new distribution agreements expected to contribute positively from the second half of next year.

In the Wholesale segment, net sales grew by 23% to EUR 91 million, supported by strong development in parallel imports in Sweden and solid performance in Finland, particularly in sales to veterinarians and in special-licensed medicines. Despite the sales growth, adjusted EBITDA remained at the previous year's level of EUR 3.1 (3.1) million, impacted by an unfavourable product mix and increased operating expenses, including personnel costs and planned marketing initiatives. For example, we recently refreshed our health and wellbeing brand, Apteekkarin, to better align with the expectations of today's consumers. Known for its good quality-to-price ratio, the brand is available exclusively in Finnish pharmacies. 

In advisory business, the positive development in digital and data services continued with double-digit growth. We have also focused on new customer acquisition with positive impact expected next year, and on building a partner network to strengthen our capabilities for EU-wide assignments.

Our strategic investment to renew Oriola's ERP (enterprise resource planning) and WMS (warehouse management systems) is progressing and we are entering deployment's first phase in Sweden.

During the quarter, Oriola was awarded the EcoVadis gold medal for sustainability for the third consecutive year. This recognition emphasises the importance of continuous improvement and integrating sustainability into our daily operations. 

In the joint venture company, Kronans Apotek, the market share remained stable at 20.9% during the third quarter, in line with the second quarter. Total sales increased by 3.0% compared with last year, driven by growth in both brick-and-mortar and e-commerce channel. The ERP integration has progressed according to plan and is expected to be completed in the fourth quarter. Completing the ERP also means finalising the integration process and setting a stable foundation for the growth.

As we approach year-end, it is essential that we stay focused on driving sales growth, improving margins and managing our cost base effectively.

I want to extend my warmest thanks to the entire Oriola team for your dedication and achievements. Your commitment is what enables us to move forwards.

Disclosure procedure

This stock exchange release is a summary of Oriola Corporation's Interim Report January-September 2025. The complete report is attached to this release in pdf format and is also available on Oriola's website at www.oriola.com.

Analyst and investor meeting at 10.00 a.m.

Oriola's CEO Katarina Gabrielson and CFO Mats Danielsson will present the report at a live webcast meeting today at 10.00 a.m. Join the meeting: https://oriola.events.inderes.com/q3-2025  

Financial calendar

Oriola will publish its Financial Statements Release for 1 January-31 December 2025 on Wednesday 25 February 2026.

The publication dates of the financial reports in 2026 are as follows:

• Interim Report 1-3/2026 on Wednesday 29 April 2026
• Half-Year Report 1-6/2026 Friday 17 July 2026
• Interim Report 1-9/2026 on Thursday 29 October 2026

Oriola Corporation's Annual General Meeting is planned to be held on Wednesday 25 March 2026. Oriola's Board of Directors will convene the Annual General Meeting at a later date. The Annual Report 2025 will be published during week 10 (latest 4 March 2026).

Further information:
Mats Danielsson
CFO
email: mats.danielsson@oriola.com

Mikael Wegmüller
VP, Communications and Sustainability
email: mikael.wegmuller@oriola.com

Distribution:
Nasdaq Helsinki Ltd
Key media

Oriola Corporation  Investor news  16 October 2025 at 9:00 a.m. EEST

Oriola Corporation to publish its Interim Report for January-September 2025 on 30 October 2025

Oriola Corporation will publish its Interim Report for January-September 2025 on Thursday 30 October 2025 at around 8:30 a.m. EET. The Interim Report will be available on Oriola's website after the publication.

Welcome to join our results presentation

CEO Katarina Gabrielson and CFO Mats Danielsson will present the Q3 results at a webcast meeting on the same day starting at 10.00 a.m. EET. The link to the webcast will be available on Oriola's website: https://www.oriola.com/investors/.

Q&A

Questions to the management can be presented through the webcast chat.

Presentation material and recording

The presentation material and a recording of the webcast will be available on Oriola's website: https://www.oriola.com/investors/reports-and-presentations/

Oriola Corporation

Further information:

Tua Stenius-Örnhjelm, Investor Relations
tel. +358 40 748 8864
investor.relations@oriola.com

Oriola Corporation  Stock Exchange Release  2 October 2025 at 2:00 p.m. EEST

Oriola appoints Maria Lundell as Chief People Officer

Maria Lundell, MA has been appointed Oriola Corporation's Chief People Officer (CPO) and member of the Oriola Management Team as of 1 November 2025. Lundell has previously worked as Executive Vice President, People and Culture at Blastr Green Steel and Senior Vice President, Human Resources at Stora Enso Paper. 

"As we continue our strategic transformation toward becoming the leading specialist in wholesale of pharmaceuticals and health products, we are happy to welcome Maria. With a proven track record in change management and organisational development, her leadership will contribute to shaping a sustainable, values-driven culture at Oriola. This appointment reinforces our commitment to building a collaborative environment where openness, responsibility, and initiative are valued," comments Oriola's CEO Katarina Gabrielson.

"Joining Oriola at this important moment is both exciting and meaningful. I'm deeply committed to developing a culture that supports the transformation journey. With my experience in change management, I look forward to aligning the company strategy with leadership development," comments Maria Lundell.

Oriola's Management Team will from 1 November 2025 consist of the following members:

• Katarina Gabrielson, CEO
• Mats Danielsson, CFO
• Katja Lundell, EVP, Advisory Services
• Maria Lundell, Chief People Officer
• Mikael Nurmi, Chief Digital Officer
• Satu Nylén, EVP, Services and Products
• Petter Sandström, General Counsel
• Tuomas Tiilikainen, Chief Supply Chain Officer
• Stig Tornell, EVP, Sales

Katarina Gabrielson
CEO

******

CV - Maria Lundell
MA
Finnish citizen

Primary career
2023-present, Blastr Green Steel Oy, Executive Vice President, People & Culture
2017-2023, Stora Enso Paper Oy, Senior Vice President, Human Resources
2016, Strategic advisory roles for Deloitte Finland Oy and Enfo Oyj
2009-2015, Enfo Oyj, Senior Vice President, Human Resources
2005-2008, Nasdaq OMX Nordic exchange, Vice President Human Resources / Managing Director, Finland, Sweden, Denmark, the Baltics, Iceland, the UK
2001-2005, L'Oréal Finland Oy, Director of Human Resources
1999-2001, Starwood Hotels & Resorts, Hotel Kämp, Human Resources Manager

******

Further information:
Katarina Gabrielson, CEO
tel. +46 72 234 8809
email: katarina.gabrielson@oriola.com

Mikael Wegmüller
VP, Communications and Sustainability
tel. +356 40 7762 314
email: mikael.wegmuller@oriola.com

Distribution:
Nasdaq Helsinki Ltd.
Key media

Oriola Corporation Stock Exchange Release 24 September 2025 at 8:45 a.m. EEST

Publication schedule for Oriola Corporation's financial reporting in 2026

Oriola Corporation will publish its Financial Statements Release for 1 January-31 December 2025 on Wednesday 25 February 2026.

The publication dates of the financial reports in 2026 are as follows:

• Interim Report 1-3/2026 on Wednesday 29 April 2026
• Half-Year Report 1-6/2026 Friday 17 July 2026
• Interim Report 1-9/2026 on Thursday 29 October 2026

Oriola Corporation's Annual General Meeting is planned to be held on Wednesday 25 March 2026. Oriola's Board of Directors will convene the Annual General Meeting at a later date. The Annual Report 2025 will be published during week 10 (latest 4 March 2026).

Oriola Corporation

Further information:
Tua Stenius-Örnhjelm, Investor Relations, tel. +358 40 7488864
investor.relations@oriola.com

Distribution:
Nasdaq Helsinki Ltd
Key media

Oriola Corporation Stock Exchange Release 18 July 2025 at 8.30 a.m. EEST

Oriola Corporation's Half-Year Report January-June 2025

Strong partnerships drive Distribution growth and profitability

April-June 2025 financial highlights

• Invoicing increased by 12.6 % to EUR 1,072.6 (952.2) million.
• Net sales increased by 12.4% to EUR 493.9 (439.4) million.
• Sales margin increased by 5.6% to EUR 42.2 (40.0) million.
• Adjusted EBITDA was EUR 8.1 (8.0) million.
• EBITDA was EUR 1.6 (8.6) million and included adjusting items of EUR -6.5 (0.5) million mainly related to the implementation cost of the ERP investment and to the sale of dose dispensing business in Sweden.
• Profit for the period totalled EUR -5.6 (2.0) million and earnings per share were EUR -0.03 (0.01).
• Free cash flow was EUR -4.2 (18.5) million.

• The sale of Svensk dos AB to Apotekstjänst Sverige AB was completed on 1 April 2025.

January-June 2025 financial highlights

• Invoicing increased by 11.4 % to EUR 2,072.8 (1,860.6) million.
• Net sales increased by 15.5% to EUR 940.9 (814.6) million.
• Sales margin increased by 4.8% to EUR 83.5 (79.7) million.
• Adjusted EBITDA was EUR 15.6 (15.7) million.
• EBITDA was EUR 7.5 (15.3) million and included adjusting items of EUR -8.1 (-0.4) million mainly related to the implementation cost of the ERP investment and to the sale of dose dispensing business in Sweden.
• Profit for the period totalled EUR -11.0 (-0.3) million and earnings per share were EUR -0.06 (-0.00).
• Free cash flow was EUR 20.8 (8.1) million.

1 Adjusting items are specified in note Adjusting items on page 19.

In order to reflect the underlying business performance and to enhance comparability between financial periods, Oriola discloses certain performance measures of historical performance, financial position and cash flows, as permitted in the "Alternative performance measures" guidance issued by the European Securities and Markets Authority (ESMA). These measures should not be considered as a substitute for measures of performance in accordance with the IFRS. The calculation methods of these measures are provided under Key financial indicators in this Interim Report.

Outlook for 2025

In 2025, the pharmaceutical distribution market is expected to continue to grow. Value growth is expected to be driven by high-value pharmaceuticals and products requiring advanced logistics. The uncertainty in the geopolitical environment remains, and the availability issues of certain pharmaceuticals are expected to continue.

Consumer confidence is expected to remain weak, which may have an impact on the wholesale market. Typically in economic uncertainty, consumers tend to shift purchases to low-price categories.

For 2025, Oriola expects the adjusted EBITDA to increase from the previous year (2024: EUR 33.4 million). The expectation of improved adjusted EBITDA is based on growing markets and strategy execution.

From the start of 2025, Oriola introduced adjusted EBITDA (earnings before interest, taxes, depreciation and amortisation) as a new alternative performance measure. EBITDA is widely used by management and investors when assessing the profitability of a company and cash flow generation.

CEO Katarina Gabrielson:

In the second quarter, net sales grew and sales margin improved, and the underlying distribution business remained strong. In the operating environment, we continue to see overall uncertainty which is reflected in continued weak consumer confidence. On the other hand, the overall pharmaceutical distribution market saw good growth.

In the second quarter, net sales grew by 12% to EUR 494 million, driven by both Distribution and Wholesale segments. Sales margin was EUR 42.2 (40.0) million, with improvement supported by the Distribution segment. The adjusted EBITDA was EUR 8.1 (8.0) million, including an increase in operational expenses from the comparison period. Operational expenses were higher due to an increase in personnel, temporary storage capacity and high peaks in orders. Freight costs were at the previous year's level despite higher volumes, reflecting a good development in the filling rate.

In the Distribution segment, net sales grew by 11% to EUR 398 million, supported by growing sales from existing portfolio, newly onboarded customers, service sales and market growth. Adjusted EBITDA increased to EUR 8.3 (6.1) million, driven by net sales growth, offsetting higher operating expenses. In the second quarter, we completed the onboarding of a new cross-market customer, supporting results for the rest of the year. The deregulation of the Finnish pharmacy market took a step forward with a new legislative proposal, indicating the width of the proposed changes in the first phase. We have been preparing for this in recent months, for instance by building our capabilities, such as creating a distribution model compliant with good distribution practice (GDP) for retail.

In the Wholesale segment, net sales grew by 18% to EUR 96 million. Growth was primarily driven by the wholesale business in Sweden, supported by good development in parallel import of weight-loss medicines. Overall sales growth in Finland remained modest. However, we achieved growth in sales to veterinarians, demonstrating our continued focus on customer centricity and our strong position in the animal health market. Adjusted EBITDA declined to EUR 2.1 (3.1) million. The fall in profitability was related to higher operating expenses due to planned increase in personnel and an unfavourable product mix due to parallel import. In the second quarter, the sale of seasonal products such as sun care and allergy products, and insect repellents, has been negatively impacted by the weather.

In advisory business, we continued to see positive development with double-digit growth in digital and data services, showing the need for high-quality market data to support customers in their decision-making. We also completed the integration of the recently acquired MedInfo in Denmark, which strengthens our Nordic footprint in medical information and patient support programmes.

We reached an important milestone with the approval of Oriola's science-based climate targets by the Science Based Targets initiative (SBTi). These targets, including ambitious near-term goals and a commitment to reach net-zero emissions across our value chain by 2050, reflect our dedication to responsible business and long-term climate action.

In the joint venture company, Kronans Apotek, the result was burdened by high costs in the second quarter. The e-commerce reached high sales with growth of 44%, further improving the e-commerce footprint, while the brick-and mortar operation saw flat sales. The overall sales growth resulted in Kronans Apotek improving its market share at the end of the period compared with the end of the first quarter. As of 1 April 2025, Kronans Apotek is now merged into one legal entity and during the second quarter the roll-out of the common ERP was started.

Our strategic investment to renew Oriola's ERP (enterprise resource planning) and WMS (warehouse management systems) is progressing according to plan. The first deployment, which is planned for a part of the operations in Sweden, is scheduled towards the end of this year. Ahead of this we have started the testing phase.

I am pleased with our progress in the second quarter, particularly the continued net sales growth and sales margin improvement, but there is still room for improvement in our profitability. In the second half of the year, we will focus on driving sales growth, further strengthening our sales margin, and implementing measures to manage our cost base. We have already implemented efficiency improvements, which provide more stable operations, and we continue with strict cost control across the company.

I would like to extend my sincere thanks to everyone at Oriola for their achievements and continued commitment to deliver on our strategic goals.

Disclosure procedure

This stock exchange release is a summary of Oriola Corporation's Half-Year Report January-June 2025. The complete report is attached to this release in pdf format and is also available on Oriola's website at www.oriola.com.

Analyst and investor meeting at 10.00 a.m.

Oriola's CEO Katarina Gabrielson and CFO Mats Danielsson will present the report at a live webcast meeting today at 10.00 a.m. Join the meeting: https://oriola.events.inderes.com/q2-2025

Financial reporting in 2025

Oriola will publish the Interim Report January-September 2025 on 30 October 2025.

Further information:
Mats Danielsson
CFO
email: mats.danielsson@oriola.com

Mikael Wegmüller
VP, Communications and Sustainability
email: mikael.wegmuller@oriola.com

Distribution:
Nasdaq Helsinki Ltd
Key media